

# Miami Jewish Health

## Enrolling Clinical Trials

Miami Campus - Marc E Agronin, MD, Principal Investigator

**Name of Study:** *AVANIR* 15-AVP-786-301/303

**Description of Study:** The TRIAD Study is a phase III study evaluating an investigational medication to see if it may reduce agitation in patients with dementia related to Alzheimer's disease.

**Indication:** Dementia of the Alzheimer's type

**Recruiting Participant Age:** 50-90 years

**Duration of Study:** approximately 4 months

**Name of Study:** *AVID* (A16 Study) 18F-AV-1451-A16

**Description of Study:** The A16 study is testing an investigational imaging dye, 18F-AV-1451, to see if it can be used in PET imaging to identify a build-up of tau protein, an abnormality found in the brains of patients with Alzheimer's disease. The study will look at the relationship between the build-up of tau protein detected by the PET scan and the buildup detected by autopsy of the brain in end-of-life subjects.

**Indication:** End Stage conditions (life expectancy  $\leq$  6 months)

**Recruiting Participant Age:** 50 years or older

**Duration of Study:** approximately 6 months

**Name of Study:** *BIOGEN* (ENGAGE Study) 221AD301 - Immunotherapy

**Description of Study:** The ENGAGE study is a phase III, global study assessing the efficacy and safety of the investigational medication Aducanumab (BIIB037). The goal is to determine whether the medication can slow the progression of symptoms in individuals with early Alzheimer's disease.

**Indication:** Early Alzheimer's disease

**Recruiting Participant Age:** 50 - 85 years

**Duration of Study:** approximately 18 months

**Name of Study:** *EISAI* E2609-G00-301

**Description of Study:** This is a phase III study, investigating a drug called Elenbecestat (E2609) in individuals with mild cognitive impairment (MCI) due to Alzheimer's disease or other early stages of mild Alzheimer's disease. The goal of the study is determine whether the drug reduces the amount of protein buildup in the brain of Alzheimer's patients, and if the potential reduction would in turn slow the progression of the disease and its associated memory loss.

**Indication:** Early Alzheimer's disease

**Recruiting Participant Age:** 50 – 85 years

**Duration of Study:** approximately 29 months

**Name of Study:** *EISAI* E2006-G000-202

**Description of Study:** This is a phase II study, evaluating if the investigational drug Lemborexant may help people with Alzheimer's stay asleep at night and stay awake more during the day.

**Indication:** Alzheimer's and ISWRD (Irregular Sleep Wake Rhythm Disorder)

**Recruiting participant Age:** 60-90 years

**Duration of Study:** approximately 4 weeks

**Name of Study:** *GENENTECH* GN39763

**Description of Study:** This is a phase II study, assessing the efficacy and safety of the investigational antibody MTAU993A for the treatment of Alzheimer's disease, targeting Tau Protein in the brain.

**Indication:** Prodromal to Mild Alzheimer's disease

**Recruiting participant Age:** 50-80 years

**Duration of Study:** approximately 24 months

**Name of Study:** *INTRACELLUAR* (201 Agitation Study) ITI-007-201

**Description of Study:** This is a phase III clinical trial testing the effectiveness and safety of an investigational medication (ITI-007), on treating symptoms of agitation associated with dementia in patients with probable Alzheimer's Disease.

**Indication:** Probable Alzheimer's disease

**Recruiting Participant Age:** 55 years or older

**Duration of Study:** approximately 2 months

**Name of Study:** *NEURIM* NEUP11-AD2

**Description of Study:** This is a phase II study evaluating the safety, tolerability, and efficacy of an investigational drug called Piromelatine in patients with mild Alzheimer's Disease.

Piromelatine may have the potential to enhance sleeping quality and patterns, which has been shown to be positively associated with overall cognitive function.

**Indication:** Mild Dementia due to Alzheimer's disease

**Recruiting Participant Age:** 60 – 85 years

**Duration of Study:** approximately 7 months

**Name of Study:** *PROCLARA* NPT088-CL002 - Immunotherapy

**Description of Study:** This is a phase I study assessing the safety and tolerability of the investigational drug NPT008 in patients with mild to moderate probable Alzheimer's disease.

The drug is intended to target multiple types of misfolded proteins in the brain of Alzheimer's patients, all which have been linked to the pathology of neurodegenerative diseases and in combination may contribute to disease progression.

**Indication:** Probable Alzheimer's disease

**Recruiting Participant Age:** 50 – 85 years

**Duration of Study:** approximately 8 months

Aventura Location- Julie Schwartzbard, MD, Principal Investigator

**Name of Study:** *ALLERGAN* UBR-MD-02

**Description of Study:** This is a phase II clinical trial testing the effectiveness and safety of an investigational medication that targets single migraine attacks. The goal of the study is to see if the medication can provide acute treatment for moderate to severe migraines.

**Indication:** Migraine with or without aura

**Recruiting Participant Age:** 18 – 75 years

**Duration of Study:** 2-3 months

**Name of Study:** *BIOTIE* TOZ-CL06

**Description of Study:** This is a phase III clinical trial evaluating the safety and efficacy of a medication called Tozadenant, which may potentially decrease daily “Wearing-Off” periods in Levodopa-treated patients with Parkinson’s disease.

**Indication:** Parkinson’s disease (PD)

**Recruiting Participant Age:** 30 – 80 years

**Duration of Study:** Up to 62 weeks

**Name of Study:** *EISAI* E2609-G00-301

**Description of Study:** This study is investigating a drug called Elenbecestat (E2609) in individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease or other early stages of mild Alzheimer’s disease. The goal of the study is determine whether the drug reduces the amount of protein buildup in the brain of Alzheimer’s patients, and if the potential reduction would in turn slow the progression of the disease and its associated memory loss.

**Indication:** Early Alzheimer’s disease

**Recruiting Participant Age:** 50 – 85 years

**Duration of Study:** approximately 29 months

If you are interested in participating or learning more about our clinical trials, please call

305-514-8710

[ESuarez@miamijewishhealth.org](mailto:ESuarez@miamijewishhealth.org)

[EDiaz1@miamijewishhealth.org](mailto:EDiaz1@miamijewishhealth.org)